Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PMM2 | O15305 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508948 | 0.90 | POLB (0.44) | POLBSCN2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL5511162 | 0.83 | SCN2A (0.36) | SCN2AKAT2BSMN1; SMN2LMNAMAPT | |
| SCHEMBL5509910 | 0.81 | MAPT (0.36) | POLBSCN2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL5508145 | 0.74 | HPGD (0.47) | POLBLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL5511798 | 0.70 | HTT (0.44) | SMN1; SMN2LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL5508840 | 0.70 | ALDH1A1 (0.44) | SCN2AALDH1A1 | |
| SCHEMBL5510401 | 0.68 | LRRK2 (0.35) | SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL5999601 | 0.68 | HPGD (0.40) | POLBLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL12727392 | 0.67 | GRM2 (0.42) | POLBSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL12768203 | 0.65 | TSHR (0.38) | SMN1; SMN2LMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812429-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | Portola Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2006039212-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | TBXAS1, TBXA2R, SERPINC1 | POLB 2201/4885SCN2A 2239/4885KAT2B 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.